Specialty Physicians Point to Permanent Changes Introduced by the COVID-19 Pandemic, Highlighting the Challenges that Lie Ahead for Pharmaceutical Manufacturers
Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains largely virtual, and many practices are unlikely to return to pre-pandemic volumes EXTON, Pa., April 7, 2021 /PRNewswire/ — Since late March 2020, Spherix has been surveying specialty physicians (dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists) in the […]
The Impact of COVID-19 on Specialty Physician Practices is Far from Over, Leaving Pharmaceutical Companies to Assess Whether Traditional Promotional Efforts Will Ever Revert to the Pre-COVID Era
According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry, particularly when it comes to in-person promotion EXTON, Pa., February 12, 2021 /PRNewswire/ — Ten months after the doors closed in response to the COVID-19 pandemic, a survey of 266 US specialty physicians conducted by Spherix Global […]
Recent Otezla Growth: A Result of the Amgen Acquisition or Benefiting from the Pandemic?
According to Spherix Global Insight’s COVID-19 tracker, dermatologists and rheumatologists alike report that they are more inclined to use Otezla than biologics or JAK inhibitors since the pandemic began in March 2020. Will that growth prevail as pandemic pressures ease? EXTON, Pa., February 10, 2021 /PRNewswire/ — Despite the potential for setbacks brought forth by the COVID-19 […]
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) and Zeposia (BMS) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis EXTON, Pa., January 29, 2020 /PRNewswire/ —Spherix Global Insights, a […]
New Research on Emerging Markets in Dermatology Reveals Vast Potential for Pipeline Agents
US dermatologists’ lack of satisfaction with current treatment options in hidradenitis suppurativa and alopecia areata paves the way for advanced systemic agents to disrupt each market EXTON, Pa., January 21, 2021 /PRNewswire/ — Spherix recently surveyed 101 US dermatologists and followed up with eleven qualitative interviews (including two with industry key opinion leaders) in order to assess […]
IL-23 Inhibitors Take Over the US Psoriasis Switching Market at the Expense of the IL-17 and TNF Inhibitors
AbbVie’s Skyrizi now garners the greatest switch-to rate, capturing the majority of new business from patients previously treated with sister-brand Humira and Amgen’s Otezla EXTON, Pa., November 17, 2020 /PRNewswire/ — The 2020 audit included in Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in Psoriasis (US) service focuses on a critical facet of overall therapy prescribing […]
Despite Most Specialty Physician Practices Reopening, Engagement with the Pharmaceutical Industry Continues to be Largely Virtual, Placing Added Pressure on Manufacturers Attempting to Introduce New Therapies
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains EXTON, Pa., September 15, 2020 / PRNewswire / – In March, Spherix began tracking the impact of COVID-19 among specialty physicians, specifically dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists. In each wave, approximately 250 specialists share […]
Spherix Global Insights Releases 2021 Publication Plan and Announces New Service, Launch Dynamix™, Fueled by Growing Client Demand
The firm, which was recently recognized by Philadelphia Business Journal as one of the area’s Soaring 76 fastest growing companies for the second year in a row, continues to invest in its areas of deep expertise: dermatology, gastroenterology, nephrology, neurology, and rheumatology EXTON, Pa., August 27, 2020 /PRNewswire/ — Since its founding in 2015, Spherix […]
Dermatologists Are Extremely Satisfied with Sanofi/Regeneron’s Dupixent in Atopic Dermatitis, Though the Brand Leaves Certain Patient Segments Untapped: Will JAK Inhibitors Be the One to Fill the Gap?
US and EU5 dermatologists are excited about the potential approvals of Eli Lilly’s Olumiant (baricitinib), Pfizer’s abrocitinib, and AbbVie’s Rinvoq (upadacitinib), though challenges likely lie ahead for the future atopic dermatitis JAKs EXTON, Pa., August 20, 2020 /PRNewswire/ — Atopic dermatitis (AD), commonly referred to as eczema, affects millions of patients across the globe. In […]
COVID-19 Continues to Disrupt Patient Care Among Specialty Physicians, Though There Are Early Signs That Recovery is on the Horizon
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing multiple challenges with re-opening EXTON, Pa., July 6, 2020 / PRNewswire / – Results from the seventh wave of an ongoing study examining the impact of COVID-19 on specialty physician practices were released last week […]